These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37591616)

  • 1. Evaluating residual anti-Xa levels following discontinuation of treatment-dose enoxaparin in patients presenting for elective surgery: an infographic.
    Henshaw DS; Schwenk ES; Gupta RK
    Reg Anesth Pain Med; 2024 Feb; 49(2):102-103. PubMed ID: 37591616
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluating residual anti-Xa levels following discontinuation of treatment-dose enoxaparin in patients presenting for elective surgery: a prospective observational trial.
    Henshaw DS; Edwards CJ; Dobson SW; Jaffe D; Turner JD; Reynolds JW; Thompson GR; Russell G; Weller R
    Reg Anesth Pain Med; 2024 Feb; 49(2):94-101. PubMed ID: 37280083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral direct factor Xa inhibitor versus enoxaparin for thromboprophylaxis after hip or knee arthroplasty: Systemic review, traditional meta-analysis, dose-response meta-analysis and network meta-analysis.
    Feng W; Wu K; Liu Z; Kong G; Deng Z; Chen S; Wu Y; Chen M; Liu S; Wang H
    Thromb Res; 2015 Dec; 136(6):1133-44. PubMed ID: 26498222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer-Associated Venous Thromboembolism Treatment With Anti-Xa Versus Weight-Based Enoxaparin: A Retrospective Evaluation of Safety and Efficacy.
    Hart K; Andrick B; Grassi S; Manikowski J; Graham J
    Ann Pharmacother; 2021 Sep; 55(9):1120-1126. PubMed ID: 33455432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The hazard of fondaparinux in non-critically ill patients with COVID-19: Retrospective controlled study versus enoxaparin.
    Prandoni P; Cattelan AM; Carrozzi L; Leone L; Filippi L; De Gaudenzi E; Villalta S; Pesavento R;
    Thromb Res; 2020 Dec; 196():395-397. PubMed ID: 33007739
    [No Abstract]   [Full Text] [Related]  

  • 6. Enoxaparin dosing after cesarean delivery in morbidly obese women.
    Overcash RT; Somers AT; LaCoursiere DY
    Obstet Gynecol; 2015 Jun; 125(6):1371-1376. PubMed ID: 26000508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity.
    Freeman A; Horner T; Pendleton RC; Rondina MT
    Am J Hematol; 2012 Jul; 87(7):740-3. PubMed ID: 22565589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Supraprophylactic Anti-Factor Xa Levels Are Associated with Major Bleeding in Neurosurgery Patients Receiving Prophylactic Enoxaparin.
    May CC; Cua S; Smetana KS; Powers CJ
    World Neurosurg; 2022 Jan; 157():e357-e363. PubMed ID: 34655821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of postpartum anti-Xa levels following enoxaparin administration to prevent venous thromboembolism using 2 weight-based protocols: a randomized controlled trial.
    Haj R; Massalha M; Eitam H; Kassabri R; Yefet E; Nachum Z
    Am J Obstet Gynecol MFM; 2023 Aug; 5(8):100988. PubMed ID: 37156466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Twice-Daily Enoxaparin among Plastic Surgery Inpatients: An Examination of Pharmacodynamics, 90-Day Venous Thromboembolism, and 90-Day Bleeding.
    Pannucci CJ; Fleming KI; Momeni A; Prazak AM; Agarwal J; Rockwell WB
    Plast Reconstr Surg; 2018 Jun; 141(6):1580-1590. PubMed ID: 29608533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Achievement of goal anti-Xa activity with weight-based enoxaparin dosing for venous thromboembolism prophylaxis in trauma patients.
    Taylor A; Huang E; Waller J; White C; Martinez-Quinones P; Robinson T
    Pharmacotherapy; 2021 Jun; 41(6):508-514. PubMed ID: 33864688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended-Duration Betrixaban Reduces the Risk of Rehospitalization Associated With Venous Thromboembolism Among Acutely Ill Hospitalized Medical Patients: Findings From the APEX Trial (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban Trial).
    Chi G; Yee MK; Amin AN; Goldhaber SZ; Hernandez AF; Hull RD; Cohen AT; Harrington RA; Gibson CM
    Circulation; 2018 Jan; 137(1):91-94. PubMed ID: 29279341
    [No Abstract]   [Full Text] [Related]  

  • 13. Characteristics and Outcomes in Patients with Venous Thromboembolism Taking Concomitant Anti-Platelet Agents and Anticoagulants in the AMPLIFY Trial.
    Cohen AT; Agnelli G; Buller HR; Gallus A; Raskob GE; Sanders P; Thompson J; Weitz JI
    Thromb Haemost; 2019 Mar; 119(3):461-466. PubMed ID: 30650446
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retrospective Evaluation of Postoperative Adverse Drug Events in Patients Receiving Rivaroxaban After Major Orthopedic Surgery Compared with Standard Therapy in a Community Hospital.
    Cieri NE; Kusmierski K; Lackie C; Van Opdorp A; Hassan AK
    Pharmacotherapy; 2017 Feb; 37(2):170-176. PubMed ID: 28028830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial.
    Weitz JI; Bauersachs R; Becker B; Berkowitz SD; Freitas MCS; Lassen MR; Metzig C; Raskob GE
    JAMA; 2020 Jan; 323(2):130-139. PubMed ID: 31935028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of anti-factor Xa monitoring in surgical patients receiving prophylactic doses of enoxaparin for venous thromboembolism prophylaxis.
    Pannucci CJ; Prazak AM; Scheefer M
    Am J Surg; 2017 Jun; 213(6):1143-1152. PubMed ID: 27692434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should we be following anti-factor Xa levels in patients receiving prophylactic enoxaparin perioperatively?
    Pannucci CJ; Rondina MT
    Surgery; 2017 Feb; 161(2):329-331. PubMed ID: 27712881
    [No Abstract]   [Full Text] [Related]  

  • 18. Apixaban versus enoxaparin in elective major orthopedic surgery: a clinical review.
    Maniscalco P; Caforio M; Imberti D; Porcellini G; Benedetti R
    Clin Appl Thromb Hemost; 2015 Mar; 21(2):115-9. PubMed ID: 25125051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study.
    Steib A; Degirmenci SE; Junke E; Asehnoune K; Figier M; Pericard C; Rohr S; Letessier E; Brunaud L; Vix M; Zobairi F; Grunebaum L; Toti F
    Surg Obes Relat Dis; 2016; 12(3):613-621. PubMed ID: 26686309
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study.
    Signorelli JR; Gandhi AS
    J Oncol Pharm Pract; 2019 Mar; 25(2):362-368. PubMed ID: 29157146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.